This morning, I woke up early to a sad announcement from Genentech that:

“The Phase III METLung study of onartuzumab (MetMab) in combination with Tarceva in MET-positive, advanced non-small cell lung cancer did not meet its primary endpoint of overall survival in a planned interim analysis. At the recommendation of an independent data monitoring committee, we are voluntarily terminating the trial. Adverse events were similar between the two arms.”

Although the full data isn’t yet available, it will be presented at a future medical conference. My guess is that ESMO in Madrid will be a possibility, if the ASCO deadline has already passed.  I’ve been avidly following the concept of MET inhibition in advanced lung cancer for both ArQule’s tivantinib and Genentech’s MetMab (onartuzumab) since the data was first presented at ESMO nearly four years ago.  These posts are still available on Pharma Strategy Blog (open access).

To read my thoughts and analysis on the results of this important trial, subscribers can sign in or sign up in the box below.

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. You are NOT PERMITTED to share access or copies of posts. If you wish to purchase a CORPORATE or MULTI-USER license or want to be able to share content PLEASE CONTACT US to purchase this. Please read the terms of use before purchasing & if you work in PR, Communications or for an agency, the guidance within it. Rates may change without notice and are non-refundable.